1-9 of 9
Ling-Yuh Huw
Close
Sort by
Journal Articles

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Clinical Trials & Observations
Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel
Journal: Blood
Blood (2024) 143 (9): 822–832.
https://doi.org/10.1182/blood.2023022348
Published: 2024
Includes: Supplemental data
Journal Articles

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Michael L. Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chavez, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Wahib Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 734.
https://doi.org/10.1182/blood-2023-174956
Published: 2023
Journal Articles

Baseline CD4 T Cells Are Associated with Improved Response to CD20-CD3 Bispecifics in Lymphoma

Christopher R. Bolen, Sumedha Roy, Ling-Yuh Huw, Katerina Hatzi, Elicia Penuel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3005.
https://doi.org/10.1182/blood-2023-186771
Published: 2023
Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

L. Elizabeth Budde, Adam J Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Hao Wu, Iris To, Michael C. Wei, Julio C. Chavez
Journal: Blood
Blood (2023) 142 (Supplement 1): 613.
https://doi.org/10.1182/blood-2023-174209
Published: 2023
Journal Articles

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Adam J. Olszewski, L. Elizabeth Budde, Julio Chavez, Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling-Yuh Huw, Song Pham, Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline
Journal: Blood
Blood (2022) 140 (Supplement 1): 3757–3759.
https://doi.org/10.1182/blood-2022-159594
Published: 2022
Journal Articles

Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Ling-Yuh Huw, Feifei Li, Anton Belousov, Hemanth Ramesha, Christopher R. Bolen, Michael C. Wei, Shen Yin, David C. Turner, Elicia Penuel
Journal: Blood
Blood (2022) 140 (Supplement 1): 6448–6449.
https://doi.org/10.1182/blood-2022-157934
Published: 2022
Journal Articles

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Francesco Passamonti, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Brian Higgins, Ling-Yuh Huw, PhD, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD, John Mascarenhas, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–40.
https://doi.org/10.1182/blood-2020-136135
Published: 2020
Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1907.
https://doi.org/10.1182/blood-2019-123652
Published: 2019
Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Genevive Hernandez, PhD, Ling-Yuh Huw, PhD, Anton Belousov, PhD, Deanna Wilson, MS, Hartmut Koeppen, MD PhD, Ron McCord, PhD, Kun Peng, PhD, Nancy L Bartlett, MD, Lihua E Budde, MD PhD, Sarit Assouline, MD, Loretta J. Nastoupil, MD MSc, Dok Hyun Yoon, MD PhD, Matthew J Matasar, MD, Brendan Bender, PhD, Antonia Kwan, MD PhD MRCPCH, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Shen Yin, PhD, Michael C Wei, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1585.
https://doi.org/10.1182/blood-2019-123933
Published: 2019